This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: And welcome to Palatine's fourth quarter and fiscal year end 2023 operating results conference call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference call is being recorded. Before we begin our remarks, I would like to remind you that statements made by Palatin are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove to be accurate and that the actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Securities and Exchange Commission. Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatin's prospects. Now, I would like to turn the call over to our host, Dr. Carl Spanner, President and Chief Executive Officer of Palatin. Please go ahead.
spk04: Thank you. Good morning, and welcome to the Palatin fourth quarter in fiscal year end 2023 call. I'm Dr. Carl Spanner, CEO and President of Palatin. With me on the call today is Steve Wiltz, Palatine's Executive Vice President, Chief Financial Officer, and Chief Operating Officer. I'll now turn the call over to Steve, and he will give financial and operating updates.
spk03: Thank you, Carl, and good morning and good afternoon, everyone. Starting with Vyleesi, as a reminder, Vyleesi is our FDA-approved commercial product for premenopausal women with hypoactive sexual desire disorder, or HSDD. The goal of the VILECI program is to demonstrate commercial product value in the marketplace. With six consecutive quarters of double-digit growth that we're going to talk about shortly, I think we're doing that. But the objective is to relicense the U.S. rights to a committed women's healthcare company, and that process is advancing rapidly. When I say nicely, we do expect that there will be a transaction that we will strongly consider later this year. More about that as we move forward. Specifically, for the fiscal fourth quarter ended June 30, 2023, Vilesi gross product sales amounted to $4.1 million. This was an increase of 20% over the prior quarter and an increase of 78% over the comparable quarter last year. Net product revenue of $1.8 million increased 47% over the prior quarter and increased 128% over the comparable quarter last year. Total prescriptions dispensed increased 16% over the prior quarter and increased 92% over the comparable quarter last year. All the value metrics are are moving in a positive direction. Refill rates, commercial insurance reimbursement, and net revenue per prescription dispense continued with impactful results and trends versus the prior quarter and comparable quarter last year. Regarding Vilisi licensees outside the U.S., Fosun Pharma, Palatin's licensee of Vilisi in China, reported its first sale in the Hanian province of China. Guangdong Pharmaceuticals, Pseudocles, Palatin's licensee of Bileci in South Korea, completed enrollment in its Phase III clinical trial, evaluating the efficacy and safety of Bileci in premenopausal women with HSDD. And data from this trial is currently anticipated by calendar year end, with a potential regulatory submission in the first half of calendar year 2024. On an additional distribution front, Palatin entered into a strategic partnership with Upscript Health, a leading direct-to-consumer telemedicine company, providing telemedicine services to pharmaceutical and medical technology companies. And we anticipate the reach for Vilisi, from an awareness standpoint, will be increasing over the coming quarters. Moving over to the financial update. For the fourth quarter, and I will also highlight certain fiscal year ended, June 30th, 2023 results. Regarding revenue, total revenue consists of gross product sales of Vileci, which is net of expenses, allowances, and accruals, and license and contract revenue. Vileci gross product sales to pharmacy distributors for the quarter ended June 30th, 2023, as I mentioned, was 4.1 million with net product revenue of 1.8 million. And this compared to gross product sales of $2.3 million and net product revenue of $0.8 million for the comparable quarter last year. Gross product sales increased 78% and net product revenue increased 128% over the comparable quarter last year. Moving to operating expenses. Total operating expenses were $12.6 million for the fourth quarter and the June 30, 2023, compared to $13.9 million for the comparable quarter last year. The decrease in operating expenses was mainly the result of the recognition of expenses during the fiscal year, June 30, 2022, in connection with the sale and issuance of our Series B and Series C redeemable convertible preferred stock, and secondarily, to lower spending on our marketing efforts during fiscal 2023. I do want to expand a comment in that regarding this $12.6 million, again, for the fourth quarter of June, fourth quarter ended June 30, 2023, this $12.6 million of operating expenses, this is actually greater than what we, if you will, had projected internally. And the reason being, we advance our programs, primarily our Phase III dry eye disease trial, which we did report on recently, hit full enrollment, that full enrollment did trigger a milestone, which triggered an expense and a payment. But I do want to note that 12.6 million expenses, operating expenses for the June 30th quarter, going forward over the next several quarters, that number, those operating expenses, will be significantly less than $12.6 million. Again, we advanced the programs. We hit some milestones. You're going to have some greater expenses. There's always going to be some timing issues in that regard. Let me move over to the cash flows. Net cash used in operations for the quarter end of June 30th, 2023 was $9.6 million compared to net cash used in operations of $7.7 million for the same period in 2022. Again, same reason as I just addressed above. We had some greater expenses due to the advancement of the programs, which is a positive thing, hitting some milestones that hit in the June 30th quarter. Palatine's net cash used in operations for the fiscal year end of June 30th, for the full fiscal year, was $28.4 million compared to net cash used in operations of $29.9 million for the same period in 2022. The decrease in net cash used in operations, which is not a significant amount, was frankly due to a number of items, including different spending levels for Vilesi, but also we did recognize some net operating losses to the state of New Jersey that generated over $4 million of non-dilutive financing. Finishing up on the financials with the net loss and the cash position, Palatine's net loss for the quarter, fiscal year ended June 3, 2023, was $10.7 million. Again, that was for the quarter, and $27.7 million for the year, respectively, compared to a net loss of $12.8 million and $36.2 million respectively for the same periods in 2022. Regarding our cash position, as of June 30th, 2023, Paliton's cash, cash equivalents, and marketable securities were approximately $11 million plus $2.9 million of accounts receivable. Those accounts receivables, 100% good. All those funds have been received in the July-August timeframe. And this compared to cash and cash equivalents of $19.6 million with 1.7 million of accounts receivables as of March 31st, 2023. You might say, hey, those accounts receivables went up a little bit. Well, we're selling more, all good. And based on our current operating plan, we believe that existing cash, cash equivalents and marketable securities and receivables will be sufficient to fund currently anticipated operating expenses through calendar year 2023. Of note, I do want to highlight that Palatine's audited financial statements for the year ended June 30th, 2023, to be included in the annual report on Form 10-K, does include an audit report from our independent registered public accounting firm, KPMG, that contains a going concern explanatory paragraph, which we have had for quite some time. With that said, I'm going to turn it back over to Carl to talk a bit more granular about our exciting development and commercial programs.
spk04: Carl? Thank you, Steve. Over the course of 2023, we've continued to successfully execute on our strategy to develop novel therapeutics based on activating the melanocortin system. As I stated previously, we are focused on establishing the melanocortin system as a target for safe and effective medicines to treat inflammatory and autoimmune diseases and to develop a pipeline of highly effective drugs with unparalleled safety. An important component of our strategy is to advance our understanding of the role of the melanocortin system in stress responses, inflammation, and tissue repair. Our research efforts are being recognized through the numerous peer-reviewed and scientific presentations by our scientists and academic collaborators. Our research efforts have allowed us to identify opportunities for novel, innovative therapeutics to design better clinical trials and are a key support for our business development activities. We have three active clinical programs based on melanocortin agonists developed from our research efforts. We're very pleased, as Steve mentioned, to have completed patient enrollment in the PL9643 Melody 1 Phase 3 study in dry eye disease and are working to deliver top-line data before calendar year end. Our Phase 2 study evaluating oral PL8177, a selective melanocortin 1 receptor agonist in ulcerative colitis patients, is on track to complete patient enrollment by calendar year end with the interim assessment data as early as calendar year end. Breakout, our phase two open label study in diabetic patients with kidney disease, is also on track for top line data in the first quarter of 2024. Some of the additional highlights for the fourth quarter and fiscal year end 23 are as follows. On the commercial front, we are pleased with Vilesi's quarter-over-quarter double-digit increases across all value metrics. Notably, net product revenue increased 47%, and prescription dispensed increased 16% over the prior quarter. We are excited that the Leacy Quarterly net product revenue continues to exceed by Leacy Quarterly operating expenses, i.e., we make some money. As an extension of our commercial efforts in sexual dysfunction, we have developed a co-formulation of our melanocortin receptor-4 agonist premelanotide with a phosphodiesterase-5 inhibitor as a treatment for men with erectile dysfunction that have failed current PD-5 inhibitor therapy. Just as an aside, remolanotide is the active ingredient in Vileci. And phosphatidase 5 inhibitors, or PD5 inhibitors, are such drugs as Viagra, Cialis, Levitra, and these are the standard of care for men with erectile dysfunction. You may not be aware, but approximately 35% of men with erectile dysfunction fail or have an inadequate response to current treatments and represent a very large underserved market. The only treatment options for these patients are highly invasive, such as penile injections or penile implants. We have previously conducted clinical trials showing the synergistic effects of combining bremalamotide with the PD-5 inhibitor as a treatment for rectal dysfunction. The large market opportunity and our clinical work support commercial development of this novel formulation, and we are planning to initiate clinical programs as early as the end of this year. Our ocular programs continue to make impressive advances. As we stated, MELODY-1 is fully enrolled and we expect data by year end. We are very excited by the emerging product profile for PL9643, which is highly differentiated from current treatments for dry eye disease with excellent ocular tolerability, broad efficacy that we believe will make PL9643 the leading treatment for dry eye disease. We presented data from the analysis of the lead in population of the MELODY-1 phase three trial at the annual meeting of the Association for Research and Vision and Ophthalmology, also known as ARVO, where PL963 demonstrated broad efficacy and statistical significance separation across multiple signs and symptoms of dry eye disease and excellent ocular tolerability and safety profile with no, I repeat, no ocular adverse events. This analysis was extremely important, allowing us to confidently set the primary sign and symptom endpoints a hierarchical ordering of secondary endpoints, the analytical methods and sample size for the double-blind segment of MELODY-1. We are very excited about the data coming out, and we believe we've done everything we can to reduce the risk of this trial and are anticipating a very positive outcome. We also presented data at ARVO on PL9588, our melanocortin-based treatment for glaucoma. In preclinical studies, PL9588 showed competitive effects on reducing intraocular pressure with a single topical dose with a magnitude of effect similar to the positive controls of Tanoprost and Timolol, which are some of the current treatments that are used, with effects lasting out to 24 hours. Importantly, we also have shown effects on optic nerve protection, which we think next-generation treatments for glaucoma are going to need. So not only do we lower the pressure with this compound, we actually protect the optic nerve. As we are preparing to advance this important program, we have already initiated regulatory discussions with the FDA. Our research efforts also made significant advances with multiple presentations at scientific meetings, publications, and peer-reviewed journals. And our expertise in the Melanocortin system and innovative clinical programs are supporting our business development activities. We have multiple ongoing discussions with potential partners for our programs, and we remain optimistic that we will enter into one or more partnerships to help advance some of these very exciting programs. As we look forward to fiscal 2024, we have significant opportunities to drive value. We have data coming from three clinical trials, initiation of two new clinical programs, continued Vilisi growth and partnerships, advances of Vilisi by our South Korean and Chinese partners. Steve and I would like to thank you for listening to the Paladin fourth quarter and fiscal year-end 2023 conference call. You can find additional information on our science and clinical programs on our website, www.paladin.com, and you can find additional information on Vilisi at the vilisi.com website. Thank you. We are now open call to questions.
spk01: Thank you very much. At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For any participants using speaker equipment, it may be necessary to pick up your handset before you press the star keys. Please pause a moment whilst we poll for any questions. Thank you. Your first question is coming from Joe Pangenis from HC Wainwright. Joe, your line is live.
spk02: Hey, guys. Good morning. A couple questions, if you don't mind. But first, you know, best of luck with consummating a Vialisi transaction. I know it's highly anticipated as you continue to show, you know, good traction by not doing that much on your end and having DTC actually show some good results. So best of luck with that. So first, on the 8177 program, I wanted to focus a little more on the upcoming data, which is, I think, anticipated around year end or maybe going into the beginning of the year. What level of data or what do you think you're going to be able to show us for that interim in UC patients?
spk04: So that's the primary endpoint data. So this is an eight-week treatment study, obviously active versus placebo. And we're looking primarily at a colonoscopy score, so an endoscopic score. So we're looking for grading. We're looking forward to see lesions, also kind of lesions to decrease and show clear evidence of healing based on the male endoscopic subscore.
spk02: Got it, got it. And then... Obviously, I mean, going back to by lease a little bit, but more for the combination that you recently announced and gave more details today with the PDE-5 combination. Any more color regarding the design that you're looking at and what kind of enrollment expectations you might have to be able to drive, say, rapid data?
spk04: Sure. So, in the The study that we're anticipating conducting, the drugs will be given co-administered, so they won't be the co-formulation. What we're looking for in the study is to determine the right ratio of remolanotide to the PD-5 inhibitor for the failure patients. The co-formulation would be used in the second, in the follow-up study to that, where we can limit the number of combinations that we have to look at. So the study, these studies are enrolled very rapidly. We've got, we probably have two clinical sites, actually Philadelphia and New York. We're working with, you know, one of the advantages is we've had, obviously, a very long history in working sexual dysfunction and ED as well. So as we reached back out to some of our key investigators, they were quite enthusiastic about conducting this study. You know, as they pointed out to us, you know, there hasn't been a new innovation in rectal dysfunction in 30 years, and these guys really don't have an alternative. So I would anticipate extremely rapid enrollment in the study.
spk02: Okay, good. And then, you know what? I will go back to Vilesi by itself for a second. So, look, I believe you guys have the wherewithal to be able to, like I said, consummate transactions because obviously, you know, you've had the ex-U.S. deals as well already in place. with upcoming news, as you alluded to. I guess let me play the opposite side of the argument. Nothing in this world is guaranteed until things are signed. So on the other end of the spectrum, if you do not, say, license it in the U.S., what potential plans or scenarios would you entertain with regard to Vilesi and what kind of potential investment you might or might not be considering?
spk03: Well, thanks for that question there, Joe. Listen, internally, we couldn't be more pleased with the results, six consecutive quarters of double-digit growth. But more importantly, we're not losing any money. In fact, we're making money on Vilesi. We have a very limited infrastructure. Our plan is the targeted profitable growth, and we're doing that. I mean, we got one point. 8 million of net sales. We anticipate that going up for the third quarter and the fourth quarter. And it's, you know, at some point, if we don't pull the trigger, and we have options, we 100% have options on pulling a trigger for a transaction for Vilesi. It's always that balance of the value now versus potentially the value later. There's many things that we could do to, and we are considering, but we're trying to balance on, well, if you do it Something here now, how does that affect the potential transaction if it's going to be a quarter or two later? And a lot of that is around distribution expansion. We are not considering adding a sales force or feed on the ground, but there's many more outlets out there, especially around the telehealth, telemedicine, i.e. with Upscripts that would like to distribute by leasing. So we are advancing those types of discussions. Those are things that we, frankly, once we do the deal, we're transferring the product over to them for a certain price, and they're selling it there. It's not going to disrupt what we're doing right now. A lot of those outlets utilize cash-only basis, but it's really a market and a patient group that we are currently not able to serve because of the way we're set up for the infrastructure and the spend. So to come back around, we have multiple options that could generate significant value and increased revenue, but not one of them is going to result in us spending money where we're not making money with Vilesi. We've been making money on Vilesi for the last several quarters, and anything we do, we'll continue in with that type of strategy.
spk02: Got it. Appreciate the color, guys.
spk01: Thank you very much. Your next question is coming from Michael Higgins of Leidenberg-Fallman. Michael, your line is live.
spk05: Thanks, Pepper. Congrats, guys. Thanks for taking the question. Congrats and continue your progress with Bileci and the rest of the pipeline. Just to follow up, if I could, on the erectile dysfunction program, Joe's asking some smart questions about the trial. I just want to Ask one more, if I could, on design, size, that type of thing, what you are able to share at this time, or do you plan to wait until you start that program?
spk04: These are pretty straightforward studies. These are, as I said, these are dosing studies that are designed to find the appropriate ratio in patients that have failed PE5 inhibitor therapy. So you'll be looking at, you know, static dose of the PD-5 inhibitor with increasing doses of remolonatide on top of that in patients that have failed PD-5 inhibitor therapy. So no real, there's no trick to these studies. They're pretty straightforward. The way, the matrix that we use to measure efficacy, you know, are well established. And so these studies, as I said, they enroll very quickly. There's lots of patients out there. Keep in mind, we've also had some discussions with potential third parties around this, and there's a high interest here. There are a lot of companies, as you are aware, that are distributing PD-5 inhibitors on a cash basis. Many of those companies have now added reimbursement, insurance reimbursement, and they're looking for new products in the ED space. So this is one where I would expect that we would be able to transact relatively early in its development process.
spk05: That's fair. We'll take a look at the other phase two that has been done. It's been many, many years, but it'll give us some sense for it. It sounds like you've got some remalinatide and PDE5 inhibitor combination data. If so, what are your plans to share that?
spk04: Well, those are published. That data is published. It's out in the public domain. You can find it.
spk05: I see. Right. I have those. I was thinking some additional work.
spk04: There are... Additional publications by third-party groups, not Nopalatin, that have looked at monotherapy, for example, of remolanoside in PD-5 inhibitive failures, showing that a significant percentage, a third of the patients that fail PD-5 inhibitive therapy can be rescued on monotherapy alone. So there's a very strong precedent here. And I think this is a program that, in our mind, represents a very low clinical risk. You have FDA-approved agents. Obviously, the PD-5 inhibitors work. Obviously, we know they work in men, and we've shown, we've treated almost 2,500 men with erectile dysfunction with remelanotide. So I think there's very strong clinical precedence here. And more importantly, there's a very high medical need here. I mean, there's a lot of men out there that just don't have other options. So we like it from the standpoint, I think both the commercial side and the development side are relatively low risk.
spk05: Yeah, and that data looks great, so we'll refer to that again in our notes. But another exciting program coming up here might be in obesity, considering it's a monocortin target that you have for your pipeline. Any update or feedback for us on interest in the obesity space?
spk04: I'll just say, I'm going to say a few of these. Steve's looking at me. He's giving me a glare. I'm going to say a few things there. Many of you, of course, know we've had a very strong interest in obesity because, in part, many of the people that may be listening to this are a little bit younger, not around as long as we have. The Melanocoron 4 receptor was probably the first validated target for obesity treatment, and most of the larger companies did have programs looking for small molecules in And unfortunately, it's a very difficult target for small molecules, but a very good one for peptides. I know, Michael, you're aware you cover set melanotide in the rhythm product. We have published on two studies that we conducted with remelanotide showing very nice weight loss using remelanotide in these patients. We also had a very nice collaboration with AstraZeneca for a number of years. So we have a tremendous experience in... the role of the monocortin system in regulating food intake and obesity with excellent compounds, good insight on how to develop small molecules. So we're quite excited about the current growth in that marketplace. And there is a coming attraction. There's an obesity week coming up in a couple of weeks. I'm sure you're well aware of that. And so I would just say stay tuned.
spk05: Definitely. I'll be down there in Dallas for that, so look forward to that. Question for you, last one, and I can jump back in the queue or keep going, you let me know, but one last one here for now anyway. It's on by Lisey. Listening to your comments on the program and your conversation, Steve, with Joe about where to go with this, and it occurs to me that with successful advancement in erectile dysfunction, you could market this as the only drug for cycle dysfunction in both men and women. That would be unique. That would get a lot of attention. Any thoughts about hanging out of the program a bit longer, at least through some phase two data with a combination study?
spk04: Since you brought the topic up about drugs for sex dysfunction, there are also clinicians that are prescribing it for men that have other types of sexual dysfunction. Sexual dysfunction due to SSRI use, low desire due to stress factors and other things. And it works very well in those. And there may be some upcoming data at a meeting about that in the near future. So I personally believe that this will be the number one treatment for both male and female sexual dysfunction.
spk03: So let me just jump in also, Michael, in that, listen, we couldn't be any more excited with the results we've had and some of the things that we're not going to elaborate on today on where we think, you know, with the right investment. very significant normative value for both patients and different types of patients, albeit the pre, the post, and the mail that you're referencing. So, you know, 100%, we're analyzing and assessing that. And we have to balance that with, okay, you have a, you know, several potential transactions that you could maybe move forward with. And, you know, even if you feel that strongly, and we do. We think there is a lot of value there. The longer we keep by leasing and we keep having these results, the more value you're going to get in the future. But we also have to balance it, you know, and being realistic, this is a tough landscape, right? We're a small biotech company and we're getting into those cash numbers where we may have to do something, you know, over the next several quarters. And And, you know, the loot of financing for some deals out there are not pretty. And we're not going to do some of those deals that are being done. I'm not trying to throw a dart or judge anybody else. You know, there are different factors that they take into account. But we are not going to be doing some of those deals that are being done that I don't think a company can recover from. So with that, we have to balance that. hey, I have a non-diluted financing, you know, and no matter what, it's going to be a good deal, but timing is a significant factor for us, and we do take into account the market landscape regarding raising funds. A quick pause on that after the Coke and the hot dog, you know, that's not the only potential collaboration that we have that could happen, and I'm not just, you know, moving away from by leasing, which we have a lot of confidence in, dry eye disease, we have obviously the data is coming out. You know, we're hoping for that nice Christmas present and the holidays there. But our other programs have interest. And, you know, that's also something, you know, a lot of times the more, the further you take your program, as long as everything's working well, you know, safety, efficacy, tolerability, those types of things, more than likely the greater value you're going to get. But you have to balance, you know, where your company is and doing what's right for the shareholders regarding you know, non-dilutive versus dilutive financing. But I want to be clear, we do have other interests. You know, Carl and I try to talk to as many people as we can, where I think it was either you or Joe asked about, you know, the 8177, the ulcerative colitis endpoints. Listen, these endpoints, this is based on a lot of conversation, not just for KOLs, but companies that would be interested. You know, it's a nice way to start with, hey, if we get the first base, do you care? And we've changed the protocol based on that type of feedback, and that was both with the dry eye disease and also with the ulcerative colitis. But to be clear, we have multiple shots on goal for cash flow coming in 100% separate than a potential equity raise.
spk05: That's great feedback. Thank you. If I may, speaking of the earlier pipeline programs and cash as well, you've talked about 9643 starting another indication, possibly by year end. It doesn't sound like that's going to happen. I just want to bring that one up. Is that still?
spk04: Sure. So, Michael, in the ocular space, we are following up with a separate compound for glaucoma. That would be the next ocular program that pending resources, obviously, we would take forward. You know, we've already started outreach to the FDA on what a trial design would look like, you know, some of the preclinical things we would need, and we'll have that feedback before year end. So we would tend to go there, in part because, you know, our goal in ICIS IV-3 coming out of the Melody I would really be to look for a partnership. So, obviously, in a partnership, we take all of the opportunity for PL9643 would be taken up by that partnership. So, that's why we've held back on some of the things we could do there. And really, we're focusing on glaucoma and also back of the eye with 9654, which we didn't talk about, but there's tremendous interest in or retinal programs, even though they're preclinical, they do represent a novel mechanism, and many people don't, many investors don't follow the scientific literature, the posters, and the things we've been presenting there, but the data is quite, really quite exciting on how this monocortin mechanism works to protect the back of the eye from damage. And that really feeds into both retinol and glaucoma. So that's why we're very excited. I mean, there's not a product out there for glaucoma, for example, that can lower the oxygen pressure and provide neuroprotection, which is really what's needed. So when we think about how we choose these programs, we do want to make sure these products are well-differentiated from what's out there in the marketplace and they have opportunities to become the leading products in their categories.
spk05: Yeah, I would very much agree with your back-of-the-eye programs. One question we had coming into this, I'll dovetail off of that, is the 9588. I think you're looking to have an I&D cleared by year-end, but you're also working with your sub-Q formulation. Any updates for us on that? And maybe that's bumping into 9654, but... So we go through.
spk04: So 9588 for glaucoma is topical administration. There, again, you'll... the progression of these types of programs are purely resource dependent. We have no impediment to moving that product forward. The data is efficient. The activities that we need are beginning to occur. It's a matter of, as Steve was saying, in a tough landscape, we do have to balance out. But I think we'll be successful in what we're doing, so I think the cash will take care of itself.
spk05: I appreciate all the feedback, guys. Thank you.
spk01: Thank you very much. We don't appear to have any further questions in the queue. I will now hand back over to Carl for any closing comments.
spk04: Yeah, I'd like to thank all of you for participating in the Palatin fourth quarter and fiscal year and 2023. I think through our presentation and the, I think the hopefully illuminating questions from the analysts, I think you've gotten a good flavor of the depth of what Paladin can deliver from a valuation standpoint. And I know there can always be frustration and disconnects between valuation and opportunity, particularly when we deal with microcap companies. But we certainly believe we're undervalued, and we certainly are going to be working hard to correct that. And we believe we have all the right things in place to do that. So thank you. Look forward to continue to update you guys, and have a great day. And thank you on behalf of Steve and myself and all the employees at Paladin.
spk01: Thank you very much. This does conclude today's conference call. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.
Disclaimer